We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleStockhead’s Ashtyn Hiron sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get...
Read ArticleSpecial Report: AdAlta and SYNthesis BioVentures Fund (SYNBV) are collaborating to form AdCella, a j...
Read ArticleIt’s been a tough couple of years for ASX health care with challenging economic conditions including...
Read ArticleTim Oldham – CEO & Managing Director – AdAlta (ASX:1AD) is a clinical-stage biotechnology comp...
Read ArticleASX health sector rises in line with broader markets in the past five days AdAlta reports positive...
Read ArticleAdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleLocal markets end slightly higher IT Sector slumps 1.2pc Small Caps led by AT1 The ASX 200 trade...
Read ArticlePhase I extension study of AD-214 tested the target Phase II dose of AD-214 in healthy volunteers A...
Read ArticleTop-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the trea...
Read Article06 Mar 2024 - A snapshot of the stocks on the move, featuring Atomo Diagnostics (ASX:AT1), AdAlta (A...
Read ArticleTo register for Friday's webinar click here. Atomo Diagnostics (ASX:AT1) has announced securing pu...
Read ArticleAtomo jumps 90pc after reporting a significant sales order AdAlta up 20pc after revealing key resu...
Read ArticleStockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small...
Read ArticleAdAlta AD-214 Phase I extension study results forecast for release at end of February Results cruci...
Read ArticleTim Oldham, CEO and Managing Director, AdAlta (ASX:1AD) is a clinical stage biotechnology company...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleAdAlta’s AD-214 Phase 1 extension study interim data reinforce safety profile and dose selection Co...
Read ArticlePainChek’s European patent HeraMed signs deal with Telstra AdAlta announced interim Phase 1 results...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleASX200 closes +1.13% higher Property stocks, Industrials and IT Sector gain more than 2% Small caps...
Read ArticleAdAlta (ASX:1AD), a clinical-stage company developing novel protein and cell therapeutic pro...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleAussie shares set to track Wall Street lower at the open CPI report will be the main focus this wee...
Read ArticleClinical stage drug discovery company AdAlta (ASX: 1AD) has completed the recruitment of healthy vol...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleASX 200, Small Ords and Emerging Co’s indices all close -0.8% in the red Only the Energy Sector f...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleMesoblast plunged over 50pc after FDA response AdAlta progresses on Phase 1 extension study ResMed...
Read ArticleFutures predict the ASX will again open in the red as US earnings season continues on and US job dat...
Read ArticleLocal shares are poised to extend losses on Friday Tech titans Apple, Amazon and Atlassian reported...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleThe ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best...
Read ArticleAdAlta (ASX:1AD) has released new data on the potential efficacy of AD-214 in humans with Id...
Read ArticleThe ASX has ended the final day of the trading week firmly in the red. All sectors were down with...
Read ArticleThe S&P ASX 200 closes 1.69% lower setting new 50-day low, with Emerging Companies index also f...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleOrphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an e...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleAmid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught...
Read ArticleShareCafeWebinar Recap – KKO, VRX, 1AD & KNO Catch up on the full presentations from Kinetiko (...
Read ArticleShareCafeAdalta (ASX:1AD) – Webinar Presentation Tim Oldham – CEO and Managing Director – AdAlta is...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleThe ASX 200 dropped 0.30% and the ASX XEC declined 0.20% Only 4 out of 11 sectors were higher, with...
Read ArticleAdAlta (1AD) welcomes two new investors associated via the Yuuwa Capital Venture Capital fund as sub...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleMGC Pharma completes pre-clinical study on CimetrA Recce Pharma close to getting Aussie patent AdAl...
Read ArticleAdAlta (1AD) has been granted its second patent by the Japanese Patent Office for its lead program,...
Read ArticleThe ASX will open marginally lower on Tuesday Overnight, Wall Street was mixed but turned negative...
Read ArticleStockhead’s Top 10 at 10, published shortly after 10.30am each trading day, highlights the best (and...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleHitIQ has entered into a two-year deal with the Premier League for its concussion management tech H...
Read ArticleThe ASX will open lower on Thursday US and European sharemarkets are on a six-day losing streak Min...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleAs with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maur...
Read ArticleTwiggy’s Tattarang has seeded a new fund called Tenmile with $250m Tenmile will focus mainly on Aus...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleAdAlta (1AD) receives a European patent from the European Patent Office for its lead product AD-124...
Read ArticleThe ASX 200 is set to open 4% lower today Wall Street crashes following higher than expected inflat...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleHighlights Today, the S&P/ASX 200 Financial sector (ASX:XFJ) traded approximately 0.843% low...
Read ArticleHighlights AdAlta’s lead i-body candidate AD-214 has bagged its first Indian patent. The patent...
Read ArticleAdAlta gets first patent in India RhinoMed to start selling Covid swaps and RAT kits in Canada AdA...
Read ArticleThe US Fed plans to reduce its bond back by US$95bn a month Nasdaq plunged another 2% ASX to open l...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 0.30% at the time of writing, compared to the broader index...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleAdAlta (1AD) has been granted a patent for its lead product AD-214 by the China National Intellectu...
Read ArticleThe ASX 200 Health Index (XHJ) is trading lower by 0.27% at the time of writing, compared to the bro...
Read ArticleWall Street tumbles, ASX to fall as oil prices spike Aussie shares are set to follow Wall Street int...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleShareCafeWebinar Recap – TNR, LBT, 1AD & LIT Catch up on the full webinar with presentation...
Read ArticleShareCafeAdAlta (ASX: 1AD) – Webinar Presentation Tim Oldham – CEO and Managing Director – AdAlta i...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleThe ASX started the week lower as a result of a drop in the energy and financial sectors. Energy sha...
Read ArticleClinical-stage biotech company AdAlta (1AD) is looking to raise up to $5.95 million through a place...
Read ArticleThe so-called ‘Santa Claus Rally’ appears to be happening again this year with the ASX notching anot...
Read ArticleFor the first time in over a month, the ASX finished a week higher than where it began — even with t...
Read ArticleClinical-stage drug developer AdAlta (1AD) has entered a trading halt while it plans and completes...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader inde...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleWall Street retreats overnight All three US stock market indexes retreated overnight, with the Dow J...
Read ArticleAdAlta (ASX:1AD) has announced an amendment to its funding agreement with MTPConnect under t...
Read ArticleAustralia’s bourse had its biggest decline since February 26 falling by over 2%. The ASX 200 fell 2....
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleThe CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure canc...
Read ArticleHighlights: AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR...
Read ArticleIt was another positive close for the Australian bourse today with energy the standout sector. The A...
Read ArticleLeading the health stocks today is Nanosonics (ASX:NAN) up 19.69% after flagging FY21 revenues of $...
Read ArticleAdAlta Limited (ASX:1AD) and Carina Biotech have announced a collaboration agreement to deve...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleWhisky manufacturer Lark Distilling Co (ASX:LRK) kept things warm during winter, leading a group of...
Read ArticleAustralian shares have extended gains for the second day in a row, rising by 0.91% despite more COVI...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleThe Aussie share market has fallen for two consecutive days, down by 0.46% today. Seven sectors were...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleShareCafeHidden Gems Webinar Recap OEL, 1AD, HRZ & LRS Catch up on the full webinar with presen...
Read ArticleShareCafeA new approach to drug discovery Presenter – Tim Oldham – CEO & Managing Director – Ad...
Read ArticleSummary The ASX 200 is trading lower by 8.60 points or 0.12% to 7,106.60 at the close, weighed d...
Read ArticleAdAlta (ASX:1AD) has announced that its commercial agreement with GE Healthcare is moving to...
Read ArticleSummary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains...
Read ArticleSummary The ASX 200 is set to close the week with narrow gains, led by a strong rally in healthc...
Read ArticleSummary The ASX 200 gained 89.50 points or 1.29% to 7021.20 amid broad-based buying. Nine of th...
Read ArticleSummary The ASX 200 is heading towards its worst performance since late February, down 2% at 692...
Read ArticleSummary Island Pharmaceuticals and AdAlta have obtained patent protection for their lead program...
Read ArticleSummary Exopharm obtained firm commitments from institutional and sophisticated investors to rai...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleSource: ShutterstockProfessional Summary Biotech penny stocks are extremely volatile, given the...
Read ArticleThe biopharmaceutical discovery and development company, Adalta Ltd [ASX:1AD] share price is higher...
Read ArticleThe AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug tri...
Read ArticleAdAlta (ASX:1AD) has soared to a one-and-a-half year high after its lead drug candidate — a molecule...
Read ArticleThe capital raising wave shows no sign of crashing with August’s total coming in at $4.7bn. Once aga...
Read ArticleA quick wrap of the ASX’s key winners and losers on Thursday, August 6. Data is taken after the mark...
Read ArticleA quick wrap of the ASX’s key winners and losers on Thursday, July 23. Data is taken after the marke...
Read ArticleA quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market...
Read ArticleAustralian biotechnology company AdAlta (ASX:1AD) says it has received Human Research Ethics...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleAt the turn of the millennium Megan Baldwin, high flying CEO of ophthalmology biotech Opthea (ASX:OP...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleShark-based biotech Adalta (ASX:1AD) is one of 17 companies that have won federal government funding...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAustralian biopharmaceutical company AdAlta (ASX:1AD) has appointed a senior and experienced...
Read ArticleFirstWave Cloud Technology (ASX: FCT) has won technology super-aggregator Digital WholeSale Solution...
Read ArticleInvesting in Small-Cap Stocks Biotech is a dynamic and profitable sector for investors. Capital vent...
Read Article“History is bunk!’’ declared industrialist Henry Ford, but unfortunately for the oro-mucosal deliver...
Read ArticleMelbourne-based company AdAlta (ASX:1AD) has signed a commercial agreement for its i-body pl...
Read ArticleNo, its not photoshopped. This ratfish was caught in deep water in northern Norway. It’s no blue wha...
Read ArticleMedical tech stock AdAlta (ASX:1AD) thinks that when it comes to immunisation, what works for sharks...
Read ArticleBiotech company AdAlta (ASX: 1AD) signed taken a significant towards monetising its proprietary tech...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleHere’s our fortnightly wrap of all the news driving ASX small cap health stocks. We last checked in...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and the worst) performing ASX small caps in morning tr...
Read ArticleAs per the announcements on ASX, all the six stocks have released updates on changes in directors’ i...
Read ArticleAdAlta (ASX: 1AD), an Australian biotechnology company on its lead i-body therapeutic AD-214...
Read ArticleHealthcare Healthcare sector comprises of the companies that offer medical services, producing medi...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
